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aris, France
ata from pathology (1), transesophageal echocardiography
TEE) (2), and, more recently, scanning and magnetic reso-
ance imaging (3) studies have shown that atherosclerotic
isease of the aortic arch is an independent risk factor for ischemic
troke, associated with a high risk of recurrent vascular events.
hese findings have been summarized in the literature (4,5)
nd confirmed in a meta-analysis (6), and establish a link
etween the presence of atherosclerotic disease in the aortic
rch and risk of ischemic stroke and vascular events.
rognostic implications. Atherosclerotic disease of the aor-
ic arch with large plaques (4 mm in thickness) is present in
ne-third of patients with cryptogenic stroke, and accounts for
ne-third of the population with total ischemic stroke age 60
ears or older who have at least 1 vascular risk factor (7). In
ddition to aortic plaque thickness, data from clinical and
ase-control studies suggest that morphologic parameters such
s ulcerations, calcifications (8), superimposed thrombus,
nd/or hypoechoic plaques may better characterize plaques
ssociated with an increased risk of complications (9).
See page 855
In this issue of the Journal, Di Tullio et al. (10) report the
esults of the APRIS (Aortic Plaque and Risk of Ischemic
troke) study, in which 255 patients with a first acute
schemic stroke and 209 stroke-free control subjects under-
ent TEE. The association between arch plaques and
ypercoagulability—and its effect on stroke risk—was as-
essed in a case-control design. All subjects were followed
rospectively for 55.1  37.2 months to assess rates of
schemic stroke and death. The authors report that patients
resenting with recent acute brain infarcts who had large
4 mm) or complex (ulcerated and/or mobile) aortic arch
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.h
From the Cardiology Department, Saint Antoine University Hospital and Medical
chool, Paris, France.laques were at increased risk of ischemic stroke. The risk
as increased 2.4-fold in those with large plaques after
djustment for demographics and other stroke risk factors,
nd by 3.3-fold when the plaques were both large and
omplex, as reported previously (4).
In a previously published study (8), we found that, among
orphologic parameters such as plaque thickness, surface
rregularities, calcifications, and hypoechoic plaques, plaque
hickness 4 mm was associated with the highest event rate.
hen we combined plaque thickness with hypoechoic plaques
r surface irregularities, no additive prognostic value was
btained. However, a very significant prognostic additive value
as observed when large plaques with no calcifications were
ompared with large plaques without calcifications. The role of
ther factors, particularly inflammation and coagulation pa-
ameters, was not investigated (9), but in a later study involving
lderly patients with ischemic stroke, we found no association
etween lupus anticoagulant concentration and prognosis (11).
Severe atherosclerosis of the aortic arch (defined as plaques
5 mm and plaques with mobile components regardless of
hickness) has been associated with higher levels of C-reactive
rotein, fibrinogen, plasmin/antiplasmin complexes, and
-dimers, but no follow-up data are available to determine
heir prognostic value (12).
In the study by Di Tullio et al. (10), compared with
ontrol subjects, stroke patients had elevated concentrations
f the coagulation factor fibrinogen (p  0.001) and
rothrombin fragment F 1.2 (p  0.04), an indicator of
hrombin generation involved in both the intrinsic and
xtrinsic coagulation mechanisms. The patients did not,
owever, have elevated levels of lupus anticoagulant (p 
.50). During follow-up, which was available in 86% of
troke patients and in all control subjects, the incidence rates
f stroke or death were significantly higher in those with
troke (133 events per 1,000 person-years) versus control
ubjects (17 events per 1,000 person-years). For the first
ime, aortic plaques were found to be associated with
ncreased event rates in subjects with prothrombin fragment
1.2 above versus below the median value (230 events per
,000 person-years vs. 85 events per 1,000 person-years,
espectively, p  0.05). In stroke patients with large
laques, event-free survival was marginally lower among
hose with prothrombin fragment F 1.2 levels above the
edian (p  0.046). However, owing to the relatively small
umber of events (12 deaths and 9 strokes) during follow-
p, the authors did not find any significant increase in the
robability of death (p  0.094) or stroke recurrence (p 
.186) (data not shown), suggesting that the concept of
oagulation activation as an important prognostic factor, in
ddition to the role of plaque thickness and complexity,
equires further evaluation.
There are several limitations to this study: cases and
ontrol subjects were not ideally balanced, with significant
ifferences between groups in terms of age, prevalence of
ypertension and diabetes, history of atrial fibrillation, and
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September 2, 2008:862–4 Editorial Commentarotid stenosis. In addition, carotid duplex Doppler exam-
nation was not performed in every subject, and coagulation
ariables were not available or interpretable in all individu-
ls. However, when the authors excluded patients and
ontrol subjects (n  40) with a history of atrial fibrillation,
rothrombin fragment F 1.2 remained significantly associ-
ted with large plaques in stroke patients versus those with
o plaques (p  0.02) (data not shown).
arkers for atherosclerosis. Thoracic aorta atherosclero-
is is also a powerful marker for generalized atherosclerosis
coronary, carotid, and peripheral arterial disease, including
neurysms) (4). Among vascular risk factors, smoking and
ypercholesterolemia are associated with severe aortic arch
laques. Plasma fibrinogen (13) and homocysteine (14)
oncentrations have been related to the severity and extent
f aortic atherosclerotic lesions. Homocysteine may induce
ndothelial dysfunction, and, thus, atheroma progression,
esulting in thrombus accretion on the atheromatous plaque,
r it may be a risk marker of atherosclerosis rather than
eing a risk factor or a causal pathway for vascular events.
Plasma fibrin D-dimers are generated, and, therefore, in-
reased in concentration, when the endogenous fibrinolytic
ystem degrades fibrin. They consist of 2 identical subunits
erived from 2 fibrin molecules. Levels of coagulation markers,
ncluding D-dimers, prothrombin fragments 1-2, and
hrombin-antithrombin complexes, are increased in patients
ith atrial fibrillation, indicating abnormal thrombogenesis. In
he study by Habara et al. (15), D-dimer levels were correlated
ith left atrial appendage thrombus, and could, therefore, be
etermined for risk stratification for thromboembolism in
atients with stroke and complex aortic plaques.
An association has also been reported between progres-
ion of aortic arch atherosclerosis and vascular events
stroke, transient ischemic attack, myocardial infarction,
nd death), with a significant separation of survival curves
etween the progression and nonprogression groups as
ssessed with a 12-month TEE on follow-up (16).
ole of new markers in risk stratification. Future studies
ill be required to clarify whether the combination of
linical, echocardiographic, and biological risk factors (in-
luding D-dimers, von Willebrand factor, high sensitivity
-reactive protein, interleukin-6, and so on) will help to
tratify more accurately the risk of thromboembolism in
atients with severe aortic arch atherosclerosis and to
etermine the prognostic impact of these markers in differ-
nt clinical settings, including recurrent strokes and other
ascular events.
Identification of atherothrombosis in the aortic arch could
e important in the treatment of patients with ischemic stroke.
everal therapeutic options, including anticoagulants, anti-
latelets, cholesterol-lowering drugs, and surgery, have been
iscussed. Two retrospective observational nonrandomized
tudies reported a potential benefit of warfarin versus antiplate-
et drugs in patients with mobile components in their aortic
laques (4). However, data from 2 randomized multicenter
tudies—FAPS (French Aortic Plaques in Stroke) (16) andARSS (Warfarin-Aspirin Recurrent Stroke Study)—which
ncluded patients with a recent ischemic stroke, showed no
vidence to demonstrate the superiority of warfarin over aspirin
n this population (9). The ARCH (Aortic arch Related
erebral Hazard) trial, which is evaluating warfarin versus
lopidogrel plus aspirin in stroke patients with aortic plaques
4 mm, will help to answer this important question. In the
eantime, oral anticoagulation therapy should be restricted to
atients with TEE-detected superimposed thrombi. Anti-
latelet therapy (aspirin or clopidogrel) is the usual treatment
ption in secondary prevention after stroke (17,18). Indications
or surgical aortic endarterectomy should be restricted to highly
elected patients with a low operative risk who have had
ultiple and documented embolic events despite receiving
ptimal medical treatment.
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